FMA
SIOX

FNY Managed Accounts’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

FNY Managed Accounts’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,390
Closed -$62.4K – 876
2017
Q3 		$76K Buy
+1,390
New +$234K 0.1% 127

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FNY Managed Accounts's SIOX Position: Q4 2017 in Review

FNY Managed Accounts sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 1,390 shares — an estimated $62.4K sold.

FNY Managed Accounts first reported a position in SIOX in Q3 2017 and held it in 1 quarter. The position peaked at $76K in Q3 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • FNY Managed Accounts reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 1,390 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $62.4K.
  • FNY Managed Accounts first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Sio Gene Therapies Inc. Common Stock position peaked at $76K in Q3 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.